Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Genelux Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- FINDINGS PROVIDE MECHANISTIC SUPPORT FOR PREVIOUSLY REPORTED CLINICAL OUTCOMES OF CLINICAL REVERSAL OF PLATINUM RESISTANCE/REFRACTORINESS FROM PHASE 2 VIRO-15 TRIAL -

GENELUX ANNOUNCES PUBLICATION OF TRANSLATIONAL ANALYSIS SUPPORTING IMMUNE ACTIVATION AND CHEMOTHERAPY SENSITIZATION WITH OLVIVEC IN OVARIAN CANCER

-- TOPLINE DATA FROM RANDOMIZED PHASE 3 ONPRIME/GOG-3076 OVARIAN CANCER REGISTRATIONAL TRIAL OF OLVI-VEC EXPECTED IN 2H26 -- -- SYSTEMIC LUNG CANCER PROGRAMS ADVANCING WITH ADDITIONAL UPDATES EXPECTED THROUGHOUT 2026 -- -- $26.3 MILLION IN CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND RESTRICTED CASH AS OF MARCH 31, 2026; EXPECTED TO FUND OPERATIONS INTO 1Q27 -- WESTLAKE VILLAGE, CALIF., MAY 07, 2026 (GLOBE NEWSWIRE) -- GENELUX CORPORATION (NASDAQ: GNLX), A LATE CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2026 AND PROVIDED GENERAL BUSINESS UPDATES.

GENELUX CORPORATION REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

-- TOPLINE DATA FROM PHASE 3 ONPRIME/GOG-3076 OVARIAN CANCER REGISTRATIONAL TRIAL OF OLVI-VEC EXPECTED IN 2H26 -- -- INTERIM SYSTEMIC LUNG CANCER DATA WITH OLVI-VEC DEMONSTRATED PARTIAL RESPONSES IN RELAPSED SMALL CELL LUNG CANCER (SCLC) AND EARLY SIGNS OF ANTI-TUMOR ACTIVITY IN NON-SMALL CELL LUNG CANCER (NSCLC); ADDITIONAL UPDATES EXPECTED THROUGHOUT 2026 --

GENELUX CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

WESTLAKE VILLAGE, CALIF., JAN. 12, 2026 (GLOBE NEWSWIRE) -- GENELUX CORPORATION (NASDAQ: GNLX), A LATE CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY, TODAY ANNOUNCED THAT THOMAS ZINDRICK, PRESIDENT, CEO AND CHAIRMAN OF THE BOARD; MATT PULISIC, CHIEF FINANCIAL OFFICER; AND DR. JASON LITTEN, CHIEF MEDICAL OFFICER, WILL PARTICIPATE IN A VIRTUAL FIRESIDE CHAT HOSTED BY BORIS PEAKER, PHD, MANAGING DIRECTOR AND SENIOR EQUITY RESEARCH ANALYST AT TITAN PARTNERS, ON MONDAY, JANUARY 19, 2026 AT 9:00 A.M. PT.

GENELUX CORPORATION ANNOUNCES UPCOMING VIRTUAL FIRESIDE CHAT HOSTED BY TITAN PARTNERS

WESTLAKE VILLAGE, CALIF., JAN. 08, 2026 (GLOBE NEWSWIRE) -- GENELUX CORPORATION (GENELUX) (NASDAQ: GNLX), A LATE CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 6,666,667 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $3.00 PER SHARE.

GENELUX CORPORATION ANNOUNCES PRICING OF $20.0 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

WESTLAKE VILLAGE, CALIF., JAN. 07, 2026 (GLOBE NEWSWIRE) -- GENELUX CORPORATION (GENELUX) (NASDAQ: GNLX), A LATE CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY, TODAY ANNOUNCED THAT IT HAS COMMENCED A PROPOSED UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON STOCK. IN ADDITION, GENELUX EXPECTS TO GRANT THE UNDERWRITER A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 15% OF THE NUMBER OF SHARES OF COMMON STOCK SOLD IN CONNECTION WITH THE PROPOSED OFFERING. ALL SHARES ARE BEING OFFERED BY GENELUX. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CUSTOMARY CLOSING CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE PROPOSED OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE PROPOSED OFFERING.

GENELUX CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

WESTLAKE VILLAGE, CALIF., JAN. 02, 2026 (GLOBE NEWSWIRE) -- GENELUX CORPORATION (NASDAQ: GNLX), A LATE CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY, TODAY ANNOUNCED THE APPOINTMENT OF JASON LITTEN, M.D., AS CHIEF MEDICAL OFFICER, EFFECTIVE JANUARY 2, 2026. DR. LITTEN WILL OVERSEE ALL CLINICAL DEVELOPMENT AND MEDICAL STRATEGY AS THE COMPANY ADVANCES OLVI-VEC THROUGH MULTIPLE UPCOMING PIVOTAL MILESTONES.

GENELUX CORPORATION ANNOUNCES APPOINTMENT OF JASON LITTEN, M.D., AS CHIEF MEDICAL OFFICER

-- LUNG CANCER PROGRAMS PROGRESSING WITH INTERIM DATA UPDATES EXPECTED IN Q4 2025 -- -- TOPLINE DATA FROM ONPRIME PHASE 3 OVARIAN CANCER REGISTRATIONAL TRIAL EXPECTED IN THE SECOND HALF OF 2026 --

GENELUX CORPORATION REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES GENERAL BUSINESS UPDATES

WESTLAKE VILLAGE, CALIF., AUG. 07, 2025 (GLOBE NEWSWIRE) -- GENELUX CORPORATION (NASDAQ: GNLX), A LATE CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2025 AND PROVIDED GENERAL BUSINESS UPDATES.

GENELUX CORPORATION REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES GENERAL BUSINESS UPDATES

WESTLAKE VILLAGE, CALIF., JULY 07, 2025 (GLOBE NEWSWIRE) -- GENELUX CORPORATION (NASDAQ: GNLX), A LATE CLINICAL-STAGE IMMUNO-ONCOLOGY COMPANY, TODAY ANNOUNCED THE APPOINTMENT OF ERIC GROEN AS GENERAL COUNSEL, CORPORATE SECRETARY, CHIEF COMPLIANCE OFFICER AND HEAD OF BUSINESS DEVELOPMENT, EFFECTIVE JULY 1, 2025.

GENELUX CORPORATION ANNOUNCES APPOINTMENT OF ERIC GROEN AS GENERAL COUNSEL, CORPORATE SECRETARY, CHIEF COMPLIANCE OFFICER AND HEAD OF BUSINESS DEVELOPMENT

Genelux Corporation

GNLX

Price

Financial Reports

No items found.

Press Releases

Genelux Corporation

GNLX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

GNLX